Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Oct 20;92(20):14103-14112.
doi: 10.1021/acs.analchem.0c03129. Epub 2020 Oct 1.

Capillary Electrophoresis-Mass Spectrometry at Trial by Metabo-Ring: Effective Electrophoretic Mobility for Reproducible and Robust Compound Annotation

Affiliations
Clinical Trial

Capillary Electrophoresis-Mass Spectrometry at Trial by Metabo-Ring: Effective Electrophoretic Mobility for Reproducible and Robust Compound Annotation

Nicolas Drouin et al. Anal Chem. .

Abstract

Capillary zone electrophoresis-mass spectrometry (CE-MS) is a mature analytical tool for the efficient profiling of (highly) polar and ionizable compounds. However, the use of CE-MS in comparison to other separation techniques remains underrepresented in metabolomics, as this analytical approach is still perceived as technically challenging and less reproducible, notably for migration time. The latter is key for a reliable comparison of metabolic profiles and for unknown biomarker identification that is complementary to high resolution MS/MS. In this work, we present the results of a Metabo-ring trial involving 16 CE-MS platforms among 13 different laboratories spanning two continents. The goal was to assess the reproducibility and identification capability of CE-MS by employing effective electrophoretic mobility (μeff) as the key parameter in comparison to the relative migration time (RMT) approach. For this purpose, a representative cationic metabolite mixture in water, pretreated human plasma, and urine samples spiked with the same metabolite mixture were used and distributed for analysis by all laboratories. The μeff was determined for all metabolites spiked into each sample. The background electrolyte (BGE) was prepared and employed by each participating lab following the same protocol. All other parameters (capillary, interface, injection volume, voltage ramp, temperature, capillary conditioning, and rinsing procedure, etc.) were left to the discretion of the contributing laboratories. The results revealed that the reproducibility of the μeff for 20 out of the 21 model compounds was below 3.1% vs 10.9% for RMT, regardless of the huge heterogeneity in experimental conditions and platforms across the 13 laboratories. Overall, this Metabo-ring trial demonstrated that CE-MS is a viable and reproducible approach for metabolomics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Typical profile obtained for the analysis of a standard mixture of cationic metabolites by CE-MS (platform 19, see Table S2) using 10% acetic acid as BGE.
Figure 2
Figure 2
Individual bias to the average and interlaboratory reproducibility of μeff as obtained for the analysis of cationic metabolite standards by 19 CE-MS platforms. Green and red lines mark bias thresholds at ±5 and ±10%, respectively. Metabolites are presented in decreasing mobility order from left to right.
Figure 3
Figure 3
Individual bias and interlaboratory variability of μeff (A) and RMT (B) as determined for the analysis of standard metabolite mixture by 16 CE-MS platforms. The green and red lines denote a 5% and 10% threshold, respectively. Metabolites are presented in decreasing mobility order from left to right.
Figure 4
Figure 4
Individual bias and interlaboratory variability of μeff for cationic metabolites in complex biological matrixes: plasma (A, C, and E) and urine (B, D, and F) at three different concentrations (undiluted: A and B; 5-times dilution: C and D; 10-times dilution: E and F) by 16 CE-MS platforms. Metabolites are presented in decreasing mobility order from left to right.

References

    1. Mahieu N. G.; Patti G. J. Anal. Chem. 2017, 89, 10397–10406. 10.1021/acs.analchem.7b02380. - DOI - PMC - PubMed
    1. van Rijswijk M.; Beirnaert C.; Caron C.; Cascante M.; Dominguez V.; Dunn W. B.; Ebbels T. M. D.; Giacomoni F.; Gonzalez-Beltran A.; Hankemeier T.; Haug K.; Izquierdo-Garcia J. L.; Jimenez R. C.; Jourdan F.; Kale N.; Klapa M. I.; Kohlbacher O.; Koort K.; Kultima K.; Le Corguille G.; et al. F1000Research 2017, 6, 1649.10.12688/f1000research.12342.1. - DOI - PMC - PubMed
    1. Rochat B. J. Am. Soc. Mass Spectrom. 2017, 28, 709–723. 10.1007/s13361-016-1556-0. - DOI - PubMed
    1. Damont A.; Olivier M.-F.; Warnet A.; Lyan B.; Pujos-Guillot E.; Jamin E. L.; Debrauwer L.; Bernillon S.; Junot C.; Tabet J.-C.; Fenaille F. J. Mass Spectrom. 2019, 54, 567–582. 10.1002/jms.4372. - DOI - PubMed
    1. Nash W. J.; Dunn W. B. TrAC, Trends Anal. Chem. 2019, 120, 115324.10.1016/j.trac.2018.11.022. - DOI

Publication types